Bioretec and Spartan Medical Enter Agreement for RemeOs Screws

Bioretec, a company dedicated to advancing biodegradable orthopedic implants signed a distribution agreement with Spartan Medical Inc. for Bioretec’s RemeOs screws for the US market. 
 
The RemeOs screws received FDA market authorization in March 2023. 
 
“Spartan Medical’s view on the commercialization of new products in the orthopedic market perfectly aligns with Bioretec’s vision for a controlled launch of RemeOs screws, which we believe is crucial in ensuring the widespread adoption and success of RemeOs screws in the times ahead. The path to choosing the distribution partnership in the United States was diligently assessed. Bioretec considered various options, ranging from collaboration with international industrial players to nationwide distribution partners, and even contemplated the possibility of engaging multiple local distributers,” said Biortec CEO Timo Lehtonen.
 
The agreement outlines a controlled US distribution launch of the RemeOs screws in selected top-tier academic centers. Also included in the agreement is a potential to sell to the US Department of Defense and the Veterans Administration healthcare market.
 
RemeOs commercialization strategy includes active participation of Bioretec’s Scientific Advisory Board and utilizes comprehensive education and training platforms.
 
The RemeOs line of products is made from a biodegradable magnesium alloy hybrid composite. RemeOs implants are absorbed and replaced by bone, which facilitates fracture healing while eliminating the need for removal surgery.